Clinical Trial

Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"

Study acronym: OVERALL
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 24, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
A multicenter, prospective, randomized and controlled study to compare the efficacy and safety of obinutuzumab and rituximab in adult ALL patients with CD20 expression.Study population is 124 patients (62 in each study group).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-06-09.
Status change: Not Yet Recruiting → Recruiting 2025-04-21
Trial Details
NCT Number NCT04920968
Lead Sponsor Maria Sklodowska-Curie National Research Institute of Oncology
Collaborators: KCRI
Conditions CD20-positive Acute Lymphoblastic Leukemia
Enrollment 124 participants
Start Date 2021-10-05
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-24